Pyridoxamine as a multifunctional pharmaceutical: Targeting pathogenic glycation and oxidative damage

Cellular and Molecular Life Sciences

Volumn 62, Issue 15, 2005, Pages 1671-1681

  Voziyan, P A ^a   Hudson, B G ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

AGE; Ageing; Atherosclerosis; Diabetes; Kidney stones; Pyridoxamine; Reactive carbonyl compounds; Reactive oxygen species

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CARBONYL DERIVATIVE; GLUCOSE; PYRIDOXAMINE; PYRIDOXINE; REACTIVE OXYGEN METABOLITE;

AMADORI REARRANGEMENT; CATALYSIS; DIABETES MELLITUS; DRUG SAFETY; DRUG TOLERABILITY; GLYCATION; IMMUNE RESPONSE; LIPID DEGRADATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; OXIDATION; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOGENESIS; PHYSIOLOGY; PROTEIN STRUCTURE; REVIEW; TOXICITY;

ANIMALS; DIABETES COMPLICATIONS; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MAILLARD REACTION; OXIDATIVE STRESS; PYRIDOXAMINE; REACTIVE OXYGEN SPECIES;

EID: 23844460628     PISSN: 1420682X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00018-005-5082-7     Document Type: Review

References (102)

1. Snell E. E. (1944) The vitamin activities of 'pyridoxal' and 'pyridoxamine'. J. Biol. Chem. 154: 313-314
2. Harris S. A., Heyl D. and Folkers K. (1944) The structure and synthesis of pyridoxamine and pyridoxal. J. Biol. Chem. 154: 315-316
3. Snell E. E. (1945) The vitamin B6 group. V. The reversible interconversion of pyridoxal and pyridoxamine by transamination reactions. J. Am. Chem. Soc. 67: 194-197
4. Braunstein A. E. (1939) The enzyme system of transamination, its mode of action and biological significance. Nature 143: 609-610
5. Cohen P. P. (1940) Transamination with purified enzyme preparations (transaminase). J. Biol. Chem. 136: 565-584
6. Braunstein A. E. and Shemyakin M. M. (1952) Theory of processes of amino acid metabolism that are catalyzed by pyridoxal enzymes. Dokl. Akad. Nauk. SSSR 85: 1115-1118
7. Metzler D. E., Ikawa M. and Snell E. E. (1954) A general mechanism for vitamin B6-catalyzed reactions. J. Am. Chem. Soc. 76: 648-652
8. Metzler D. E. (1979) Tautomerism in pyridoxal phosphate and in enzymatic catalysis. Adv. Enzymol. Relat. Areas Mol. Biol. 50: 1-40
9. Metzler D. E. and Snell E. E. (1955) Spectra and ionization constants of the vitamin B6 group and related 3-hydroxypyridine derivatives. J. Am. Chem. Soc. 77: 2431-2437
10. Williams V. R. and Neilands J. B. (1954) Apparent ionization constants, spectral properties and metal chelation of the cotransaminases and related compounds. Arch. Biochem. 53: 56-70
11. Gustafson R. L. and Martell A. E. (1957) Stabilities of metal chelates of pyridoxamine. Arch. Biochem. Biophys. 68: 485-498
12. 6). Inorg. Chim. Acta 46: 199-203
13. Dawson R. M. C., Elliott D. C., Elliott W. H. and Jones K. M. (1986) Data for Biomedical Research, 3rd ed, Clarendon Press, Oxford, p. 412
14. Middleton H. M. 3rd (1986) Intestinal hydrolysis of pyridoxal 5′-phosphate in vitro and in vivo in the rat. Effect of protein binding and pH. Gastroenterology. 91: 343-350
15. Merrill A. H. Jr and Henderson J. M. (1990) Vitamin B6 metabolism by human liver. Ann. N. Y. Acad. Sci. 585: 110-117
16. Sakurai T., Asakura T., Mizuno A. and Matsuda M. (1992) Absorption and metabolism of pyridoxamine in mice. I. Transformation of pyridoxamine to pyridoxal in intestinal tissues. J. Nutr. Sci. Vitaminol. (Tokyo) 38: 227-233
17. Sampson D. A. and O'Connor D. K. (1989) Response of B-6 vitamers in plasma, erythrocytes and tissues to vitamin B-6 depletion and repletion in the rat J. Nutr. 119: 1940-1948
18. Sampson D. A. and O'Connor D. K. (1989) Analysis of B-6 vitamers and pyridoxic acid in plasma, tissues and urine using high performance liquid chromatography. Nutr. Res. 9: 259-272
19. Bisp M. R., Bor M. V., Heinsvig E. M., Kall M. A. and Nexo E. (2002) Determination of vitamin B6 vitamers and pyridoxic acid in plasma: development and evaluation of a high-performance liquid chromatographic assay. Anal. Biochem. 305: 82-89
20. Degenhardt T. P., Alderson N. L., Arrington D. D., Beattie R. J., Basgen J. M., Steffes M. W. et al. (2002) Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. 61: 939-950
21. Booth A. A., Khalifah R. G., Todd P. and Hudson B. G. (1997) In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-amadori glycation pathways. J. Biol. Chem. 272: 5430-5437
22. Booth A. A., Khalifah R. G., and Hudson B. G. (1996) Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem. Biophys. Res. Commun. 220: 113-119
23. Soulis-Liparota T., Cooper M., Papazoglou D., Clarke B. and Jerums G. (1991) Retardation by aminoguanidine of development of albuminuria, mesangial expansion and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40: 1328-1334
24. Osicka T. M., Yu Y., Panagiotopoulos S., Clavant S. P., Kiriazis Z., Pike R. N. et al. (2000) Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. Diabetes 49: 87-93
25. Rahbar S. and Figarola J. L. (2003) Novel inhibitors of advanced glycation endproducts. Arch. Biochem. Biophys. 419: 63-79
26. Stitt A.W., Frizzell N. and Thorpe S. R. (2004) Advanced glycation and advanced lipoxidation: possible role in initiation and progression of diabetic retinopathy. Curr. Pharm. Des. 10: 3349-3360
27. Gooch C. and Podwall D. (2004) The diabetic neuropathies. Neurologist 10: 311-322
28. Basta G., Schmidt A. M. and De Caterina R. (2004) Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc. Res. 63: 582-592
29. Thorpe S. R. and Baynes J. W. (2003) Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 25: 275-281
30. Wendt T., Tanji N., Guo J., Hudson B. I., Bierhaus A., Ramasamy R. et al. (2003) Glucose, glycation and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J. Am. Soc. Nephrol. 14: 1383-1395
31. Brownlee M. (1995) Advanced protein glycosylation in diabetes and aging. Annu. Rev. Med. 46: 223-234
32. Colaco C. A. and Harrington C. R. (1994) Glycation: a pathological modification in neuropathies?: a hypothesis. Neuroreport 5: 859-861
33. Thorpe S. R. and Baynes J. W. (1996) Role of the maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging 9: 69-77
34. Khalifah R. G., Todd P., Booth A. A., Yang S. X., Mott J. D. and Hudson B. G. (1996) Kinetics of nonenzymatic glycation of ribonuclease a leading to advanced glycation end products. Paradoxical inhibition by ribose leads to facile isolation of protein intermediate for rapid post-amadori studies. Biochemistry 35: 4645-4654
35. Khalifah R. G., Baynes J. W. and Hudson B. G. (1999) Amadorins: novel post-amadori inhibitors of advanced glycation reactions. Biochem. Biophys. Res. Commun. 257: 251-258
36. Voziyan P. A., Khalifah R. G., Thibaudeau C., Yildiz A., Jacob J., Serianni A. S. et al. (2003) Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of amadori intermediate to advanced glycation end-products through binding of redox metal ions. J. Biol. Chem. 278: 46616-46624
37. Price D. L., Rhett P. M., Thorpe S. R. and Baynes J. W. (2001) Chelating activity of advanced glycation end-product inhibitors. J. Biol. Chem. 276: 48967-48972
38. Stitt A., Gardiner T. A., Alderson N. L., Canning P., Frizzell N., Duffy N. et al. (2002) The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51: 2826-2832
39. Alderson N. L., Chachich M. E., Frizzell N., Canning P., Metz T. O., Januszewski A. S. et al. (2004) Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat Diabetologia 47: 1385-1395
40. Wells-Knecht K. J., Zyzak D. V., Litchfield J. E., Thorpe S. R. and Baynes J. W. (1995) Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 34: 3702-3709
41. Hayashi T. and Namiki M. (1986) Role of sugar fragmentation in the Maillard reaction. In: Amino-Carbonyl Reactions in Food and Biological Systems, p. 29-38, Fujimaki M., Namiki M. and Kato H. (eds), Elsevier, Amsterdam
42. Thornalley P. J., Langborg A. and Minhas H. S. (1999) Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem. J. 344 Pt 1: 109-116
43. Wells-Knecht M. C., Thorpe S. R. and Baynes J. W. (1995) Pathways of formation of glycoxidation products during glycation of collagen. Biochemistry 34: 15134-15141
44. Phillips S. A. and Thornalley P. J. (1993) The formation of methylglyoxal from triose phosphates. Investigation using a specific assay for methylglyoxal. Eur J. Biochem. 212: 101-105
45. Dunn J. A., Ahmed M. U., Murtiashaw M. H., Richardson J. M., Walla M. D., Thorpe S. R. et al. (1990) Reaction of ascorbate with lysine and protein under autoxidizing conditions: formation of N epsilon-(carboxymethyl)lysine by reaction between lysine and products of autoxidation of ascorbate. Biochemistry 29: 10964-10970
46. Anderson M. M., Hazen S. L., Hsu F. F. and Heinecke J. W. (1997) Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxy-amino acids into glycolaldehyde, 2-hydroxypropanal and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta-unsaturated aldehydes by phagocytes at sites of inflammation. J. Clin. Invest. 99: 424-432
47. Mlakar A. and Spiteller G. (1994) Reinvestigation of lipid peroxidation of linolenic acid. Biochim. Biophys. Acta 1214: 209-220
48. Wells-Knecht K. J., Lyons T. J., McCance D. R., Thorpe S. R., Feather M. S. and Baynes J. W. (1994) 3-Deoxyfructose concentrations are increased in human plasma and urine in diabetes. Diabetes 43: 1152-1156
49. McLellan A. C., Thornalley P. J., Benn J. and Sonksen P. H. (1994) Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin. Sci. 87: 21-29
50. Haik G. M. Jr, Lo T. W and Thornalley P. J. (1994) Methylglyoxal concentration and glyoxalase activities in the human lens. Exp. Eye Res. 59: 497-500
51. Odani H., Shinzato T., Matsumoto Y., Usami J. and Maeda K. (1999) Increase in three alpha,beta-dicarbonyl compound levels in human uremic plasma: specific in vivo determination of intermediates in advanced Maillard reaction. Biochem. Biophys. Res. Commun. 256: 89-93
52. Lapolla A., Flamini R., Dalla Vedova A., Senesi A., Reitano R., Fedele D. et al. (2003) Glyoxal and methylglyoxal levels in diabetic patients: quantitative determination by a new GC/MS method. Clin. Chem. Lab Med. 41: 1166-1173
53. Beisswenger P. J., Howell S. K., Nelson RG., Mauer M. and Szwergold B. S. (2003) Alpha-oxoaldehyde metabolism and diabetic complications. Biochem. Soc. Trans. 31: 1358-1363
54. Phillips S. A., Mirrlees D. and Thornalley P. J. (1993) Modification of the glyoxalase system in streptozotocin-induced diabetic rats. Effect of the aldose reductase inhibitor statil. Biochem. Pharmacol. 46: 805-811
55. Onorato J. M., Jenkins A. J., Thorpe S. R. and Baynes J. W. (2000) Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J. Biol. Chem. 275: 21177-21184
56. Voziyan P. A., Metz T. O., Baynes J. W. and Hudson B. G. (2002) A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J. Biol. Chem. 277: 3397-3403
57. Nagaraj R. H., Sarkar P., Mally A., Biemel K. M., Lederer M. O. and Padayatti P. S. (2002) Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal. Arch. Biochem. Biophys. 402: 110-119
58. Amarnath V., Amarnath K., Davies S. and Roberts L. J. 2nd (2004) Pyridoxamine: an extremely potent scavenger of 1,4-dicarbonyls. Chem. Res. Toxicol. 17: 410-415
59. Metz T. O., Alderson N. L., Chachich M. E., Thorpe S. R. and Baynes J. W. (2003) Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J. Biol. Chem. 278: 42012-42019
60. Iacovella G., Alderson N. L., Chachich M., Thorpe S. R. and Baynes J. W. (2003) Pyridoxamine decreases levels of reactive alpha-dicarbonyls in plasma of ZDF diabetic rats. Diabetes 52: A187
61. Alderson N. L., Chachich M. E., Youssef N. N., Beattie R. J., Nachtigal M., Thorpe S. R. et al. (2003) The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int. 63: 2123-2133
62. Shimoi K., Okitsu A., Green M. H., Lowe J. E., Ohta T., Kaji K. et al. (2001) Oxidative DNA damage induced by high glucose and its suppression in human umbilical vein endothelial cells. Mutat. Res. 480-481: 371-378
63. Menon M. and Koul H. (1992) Clinical review 32: calcium oxalate nephrolithiasis. J. Clin. Endocrinol Metab. 74: 703-707
64. Robertson W. G. and Peacock M. (1980) The cause of idiopathic calcium stone disease: hypercalciuria or hyperoxaluria? Nephron 26: 105-110
65. Holmes R. P. and Assimos D. G. (1998) Glyoxylate synthesis, and its modulation and influence on oxalate synthesis. J. Urol. 160: 1617-1624
66. Chetyrkin S. V., Kim D., Belmont J. M., Scheinman J. I., Hudson B. G. and Voziyan P. A. (2005) Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria. Kidney Int. 67: 53-60
67. Zheng F., Leclercq B., Elliot J., Striker L. J. and Striker G. E. (2002) Reduction of glomerular lesions and albuminuria in db/db mice with established diabetic nephropathy following pyridoxamine treatment. J. Am. Soc. Nephrol. 13: 534A-535A
68. Cameron N., Cotter M., Alderson N. L., Thorpe S. R. and Baynes J. W. (2003) Pyridoxamine treatment improves nerve function in diabetic rats. Diabetes 52: A192
69. Metz T. O., Alderson N. L., Thorpe S. R. and Baynes J. W. (2003) Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch. Biochem. Biophys. 419: 41-49
70. Thornalley P. J., Yurek-George A. and Argirov O. K. (2000) Kinetics and mechanism of the reaction of aminoguanidine with the alpha-oxoaldehydes glyoxal, methylglyoxal and 3-deoxyglucosone under physiological conditions. Biochem. Pharmacol. 60: 55-65
71. Mossine V. V., Linetsky M., Glinsky G. V., Ortwerth B. J. and Feather M. S. (1999) Superoxide free radical generation by Amadori compounds: the role of acyclic forms and metal ions. Chem. Res. Toxicol. 12: 230-236
72. Smith P. R. and Thornalley P. J. (1992) Mechanism of the degradation of non-enzymatically glycated proteins under physiological conditions. Studies with the model fructosamine, N epsilon-(1-deoxy-D-fructos-1-yl)hippuryl-lysine. Eur. J. Biochem. 210: 729-739
73. Wolff S. P. and Dean R. T. (1987) Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem. J. 245: 243-250
74. Yim M. B., Yim H. S., Lee C., Kang S. O. and Chock P. B. (2001) Protein glycation: creation of catalytic sites for free radical generation. Ann. N. Y. Acad. Sci. 928: 48-53
75. Halliwell B. and Gutteridge J. M. C. (1999) Free radicals in biology and medicine, 3rd ed Oxford University Press, London
76. Riedle B. and Kerjaschki D. (1997) Reactive oxygen species cause direct damage of Engelbreth-Holm-Swarm matrix. Am. J. Pathol. 151: 215-231
77. Ookawara T., Kawamura N., Kitagawa Y. and Taniguchi N. (1992) Site-specific and random fragmentation of Cu,Zn-superoxide dismutase by glycation reaction. Implication of reactive oxygen species. J. Biol. Chem. 267: 18505-18510
78. Brownlee M. (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820
79. Lee H. B., Yu M. R., Yang Y., Jiang Z. and Ha H. (2003) Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J. Am. Soc. Nephrol. 14: S241-245
80. Mikkelsen R. B. and Wardman P. (2003) Biological chemistry of reactive oxygen and nitrogen and radiation-induced signal transduction mechanisms. Oncogene 22: 5734-5754
81. Takano H., Zou Y., Hasegawa H., Akazawa H., Nagai T. and Komuro I. (2003) Oxidative stress-induced signal transduction pathways in cardiac myocytes: involvement of ROS in heart diseases. Antioxid. Redox Signal. 5: 789-794
82. Miyata T., van Ypersele de Strihou C., Ueda Y., Ichimori K., Inagi R., Onogi H. et al. (2002) Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J. Am. Soc. Nephrol. 13: 2478-2487
83. Daumer K. M., Khan A. U., and Steinbeck M. J. (2000) Chlorination of pyridinium compounds. Possible role of hypochlorite, N-chloramines and chlorine in the oxidation of pyridinoline cross-links of articular cartilage collagen type II during acute inflammation. J. Biol. Chem. 275: 34681-34692
84. Jain S. K. and Lim G. (2001) Pyridoxine and pyridoxamine inhibits superoxide radicals and prevents lipid peroxidation, protein glycosylation and (Na++ K+)-ATPase activity reduction in high glucose-treated human erythrocytes. Free Radic. Biol. Med. 30: 232-237
85. Cahuana G. M., Tejedo J. R., Jimenez J., Ramirez R., Sobrino F. and Bedoya F. J. (2004) Nitric oxide-induced carbonylation of Bcl-2, GAPDH and ANT precedes apoptotic events in insulin-secreting RINm5F cells. Exp. Cell Res. 293: 22-30
86. Kannan K. and Jain S.K. (2004) Effect of vitamin B6 on oxygen radicals, mitochondrial membrane potential and lipid peroxidation in H2O2-treated U937 monocytes. Free Radic. Biol. Med. 36: 423-428
87. Takatori A., Ishii Y., Itagaki S., Kyuwa S. and Yoshikawa Y. (2004) Amelioration of the beta-cell dysfunction in diabetic APA hamsters by antioxidants and AGE inhibitor treatments. Diabetes Metab. Res. Rev. 20: 211-218
88. Giardino I., Fard A. K., Hatchell D. L. and Brownlee M. (1998) Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation and oxidant-induced apoptosis. Diabetes 47: 1114-1120
89. Degenhardt T. P., Khalifah R. G., Klaich G. M. and Schotzinger R. J. (2002) Pharmacokinetics, tolerability and biologic activity of oral Pyridorin™, a novel AGE inhibitor, in patients with type 1 diabetes and diabetic nephropathy. J. Am. Soc. Nephrol. 13: 652A
90. Williams M. E., Bolton W. K., Degenhardt T. P. and Schotzinger R. J. (2003) A phase 2 clinical trial of pyridoxamine (Pyridorin™) in type 1 and type 2 diabetic patients with overt nephropathy (PYR-206). J. Am. Soc. Nephrol. 14: 7A
91. Abdel-Rahman E. and Bolton W. K. (2002) Pimagedine: A novel therapy for diabetic nephropathy. Expert. Opin. Investig. Drugs 11: 565-574
92. Khalifah R. G., Chen Y., Wassenberg J. and Price D. L. (2005) Post-Amadori inhibition of glycoxidation: metal ion binding as a necessary but not sufficient requirement for inhibitors. Ann. N. Y Acad. Sci., in press
93. Culbertson S. M., Enright G. D. and Ingold K. U. (2003) Synthesis of a novel radical trapping and carbonyl group trapping anti-AGE agent: a pyridoxamine analogue for inhibiting advanced glycation (AGE) and lipoxidation (ALE) end products. Org. Lett. 5: 2659-2662
94. Culbertson S. M., Vassilenko E. I., Morrison L. D. and Ingold K. U. (2003) Paradoxical impact of antioxidants on post-Amadori glycoxidation: counterintuitive increase in the yields of pentosidine and N epsilon-carboxymethyllysine using a novel multifunctional pyridoxamine derivative. J. Biol. Chem. 278: 38384-38394
95. Engelgau M. M., Narayan K. M., Saaddine J. B. and Vinicor F. (2003) Addressing the burden of diabetes in the 21st century: better care and primary prevention. J. Am. Soc. Nephrol. 14: S88-91
96. Barrett E. (2004) Diabetes epidemic is a worldwide threat Clin. Diabetes 22: 47-48
97. Baynes J. W. and Thorpe S. R. (2000) Glycoxidation and lipoxidation in atherogenesis. Free Radic. Biol. Med. 28: 1708-1716
98. Dukic-Stefanovic S., Schinzel R., Riederer P. and Munch G. (2001) Ages in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs? Biogerontology 2: 19-34
99. Baynes J. W. (2002) The Maillard hypothesis on aging: time to focus on DNA. Ann. N. Y. Acad. Sci. 959: 360-367
100. Pedchenko V., Zent R. and Hudson B. G. (2004) Alpha(v)beta3 and alpha(v)beta5 integrins bind both the proximal RGD site and non-RGD motifs within noncollagenous (NC1) domain of the alpha3 chain of type IV collagen: Implication for the mechanism of endothelial cell adhesion. J. Biol. Chem. 279: 2772-2780
101. Halliwell B. and Gutteridge J. M. C. (1986) Hydroxyl radicals assayed by aromatic hydroxylation and deoxyribose degradation. In: Handbook of Methods for Oxygen Radical research, p. 177-180, Greenwald R.A. (ed.), CRC Press, Boca Raton
102. Mehansho H., Buss D. D., Hamm M. W. and Henderson L. M. (1980) Transport and metabolism of pyridoxine in rat liver. Biochim. Biophys. Acta 631: 112-123